BKBernd Kronenberger

Bernd Kronenberger

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bernd Kronenberger has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Intrahepatic Stones

    by Bernd Kronenberger

  • Common Bile Duct Stones

    by Bernd Kronenberger

  • Acute Cholangitis

    by Bernd Kronenberger

  • Combined percutaneous retrograde and peroral antegrade esophagoscopy for the treatment of complete upper esophageal obstruction

    by Christian M. Lange, Bernd Kronenberger, Johannes Hausmann, Stefan Zeuzem, Jörg Albert

    Complete upper esophageal obstruction is a rare but significant complication of, for example, radiotherapy or caustic ingestion. It may be resolved by endoscopic techniques [1] [2] [3] [4]. Here, we report three patients with complete or nearly complete upper esophageal obstruction after curative radiochemotherapy for head and neck cancers, in whom classic peroral insertion of a guidewire for esophageal dilation failed. However, in all of these patients, esophageal stenosis was successfully treated by the combinination of a percutaneous retrograde and a peroral antegrade endoscopic approach. The length of the stenoses in these patients ranged from 2 to 20 mm ([Fig. 1]). Retrograde esophagoscopy was accomplished with an ultraslim gastroscope through an existing percutaneous gastrostomy. At the same time, peroral antegrade esophagoscopy was performed to enable diaphanoscopy-guided recanalization of the esophageal stenosis with a needle knife ( [Fig. 1], [Video 1]). Afterward, a stomach tube was placed, and the reconstructed esophageal neolumen was allowed to heal for 2 to 4 weeks. Subsequently, the patients have undergone conventional esophageal dilation procedures, which have been ongoing for 4 to 24 months ([Fig. 1]). Meanwhile, all the patients can be nourished orally and have experienced a significant increase in body weight and improvement in quality of life. No relevant complications have been observed in these patients during the entire course of endoscopic treatment. In conclusion, the combination of a percutaneous retrograde and a peroral antegrade endoscopic approach can be safe and efficient for the treatment of complete upper esophageal stenosis. Endoscopy_UCTN_Code_TTT_1AO_2AD

  • A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial

    by Jörg G. Albert, Katja Lucas, Natalie Filmann, Eva Herrmann, Oliver Schröder, Christoph Sarrazin, Jörg Trojan, Bernd Kronenberger, Jörg Bojunga, Stefan Zeuzem, et al.

    Jörg G. Albert, Katja Lucas, Natalie Filmann et al. A novel, stiff-shaft, flexible-tip guidewire for cannulation of biliary stricture during endoscopic retrograde cholangiopancreatography: a randomized trial. Endoscopy 2014; 46: 857 – 861 DOI 10.1055/s-0034-1377628 Fig. 1 was incorrect: Novel guidewire, success after “Crossover” should read “2” and not “6” as in the Fig. 1 below:

  • Telaprevir drug monitoring during antiviral therapy of hepatitis C graft infection after liver transplantation

    by Harald Farnik, Tim Zimmermann, Eva Herrmann, Wolf O. Bechstein, Bernd Kronenberger, Peter R. Galle, Sandra Labocha, Nerea Ferreiros, Gerd Geisslinger, Stefan Zeuzem, et al.

    Background & Aims Recurrence of hepatitis C virus (HCV) infection after orthotopical liver transplantation (OLT) is common and associated with reduced graft and patient survival. The protease inhibitor telaprevir may enhance virological response rates in patients after OLT in combination with pegylated interferon‐alfa and ribavirin. Pharmacokinetic studies have shown significant drug–drug interactions between telaprevir and immunosuppression (IS), but telaprevir pharmacokinetics in OLT patients with IS are unknown. Aim of the present study was to analyse telaprevir plasma concentrations in patients with HCV genotype 1 infection after OLT in comparison to patients without OLT and IS. Methods Five patients with HCV genotype 1 infection after OLT and 37 HCV genotype 1‐infected patients patients without prior OLT were treated with telaprevir 2250 mg daily, ribavirin 1000/1200 mg daily and pegylated interferon‐alfa‐2a 180 μg once weekly (triple therapy). Telaprevir plasma concentrations were analysed by liquid chromatography–electrospray‐ionization‐tandem mass spectrometry. HCV RNA was assessed by automatized reverse‐transcription polymerase chain‐reaction. Results Median (range) telaprevir plasma concentrations of TW 4, 8 and 12 were 3970 (1980–4430) ng/ml and 2520 (1870–8730) ng/ml in patients after OLT and ciclosporin‐ or tacrolimus‐based IS, respectively, as compared to 2790 (1870–3140) in non‐OLT patients (P = 0.3). In one patient with tacrolimus‐based IS, telaprevir dose had to be adjusted to achieve virological response. Telaprevir plasma concentrations were steady at treatment weeks 4, 8 and 12 in patients with and without IS. Conclusions Telaprevir drug monitoring may be necessary in patients with tacrolimus‐based IS in patients with HCV graft infection after OLT.


  • Open Access

    Interleukin-22 predicts severity and death in advanced liver cirrhosis: a prospective cohort study

    by Bernd Kronenberger, Ina Rudloff, Malte Bachmann, Friederike Brunner, Lisa Kapper, Natalie Filmann, Oliver Waidmann, Eva Herrmann, Josef Pfeilschifter, Stefan Zeuzem, et al.

    Interleukin-22 (IL-22), recently identified as a crucial parameter of pathology in experimental liver damage, may determine survival in clinical end-stage liver disease. Systematic analysis of serum IL-22 in relation to morbidity and mortality of patients with advanced liver cirrhosis has not been performed so far. This is a prospective cohort study including 120 liver cirrhosis patients and 40 healthy donors to analyze systemic levels of IL-22 in relation to survival and hepatic complications. A total of 71% of patients displayed liver cirrhosis-related complications at study inclusion. A total of 23% of the patients died during a mean follow-up of 196 ± 165 days. Systemic IL-22 was detectable in 74% of patients but only in 10% of healthy donors (P < 0.001). Elevated levels of IL-22 were associated with ascites (P = 0.006), hepatorenal syndrome (P < 0.0001), and spontaneous bacterial peritonitis (P = 0.001). Patients with elevated IL-22 (>18 pg/ml, n = 57) showed significantly reduced survival compared to patients with regular (≤18 pg/ml) levels of IL-22 (321 days versus 526 days, P = 0.003). Other factors associated with reduced overall survival were high CRP (≥2.9 mg/dl, P = 0.005, hazard ratio (HR) 0.314, confidence interval (CI) (0.141 to 0.702)), elevated serum creatinine (P = 0.05, HR 0.453, CI (0.203 to 1.012)), presence of liver-related complications (P = 0.028, HR 0.258, CI (0.077 to 0.862)), model of end stage liver disease (MELD) score ≥20 (P = 0.017, HR 0.364, CI (0.159 to 0.835)) and age (P = 0.011, HR 0.955, CI (0.922 to 0.989)). Adjusted multivariate Cox proportional-hazards analysis identified elevated systemic IL-22 levels as independent predictors of reduced survival (P = 0.007, HR 0.218, CI (0.072 to 0.662)). In patients with liver cirrhosis, elevated systemic IL-22 levels are predictive for reduced survival independently from age, liver-related complications, CRP, creatinine and the MELD score. Thus, processes that lead to a rise in systemic interleukin-22 may be relevant for prognosis of advanced liver cirrhosis.


  • Open Access

    Portal vein thrombosis as complication of romiplostim treatment in a cirrhotic patient with hepatitis C-associated immune thrombocytopenic purpura

    by Georg Dultz, Bernd Kronenberger, Alireza Azizi, Ulrike Mihm, Thomas J. Vogl, Ulrike Sarrazin, Christoph Sarrazin, Stefan Zeuzem, Wolf-Peter Hofmann


  • T2005 Dynamics of Apoptotic Activity in Patients With Chronic Hepatitis C Treated With Albinterferon Alfa-2B or Peginterferon Alfa-2a

    by Bernd Kronenberger, Eva Herrmann, C. Chen, M. Fiscella, Mani Subramanian, John McHutchison, Yves Benhamou, Mark Sulkowski, David R. Nelson, Stefan Zeuzem